Latest Shareholder Support News

Apiam Animal Health shareholders convened on 3 February 2026 to vote on a scheme of arrangement proposing acquisition by Adamantem Capital Fund II, with the board unanimously recommending approval. The scheme offers $0.87 cash per share or scrip alternatives, pending final court approval.

Cannindah Resources has raised $15 million through a two-tranche placement and launched a $2 million share purchase plan to fund expanded exploration at its Mt Cannindah Copper-Gold Project.

PYC Therapeutics has launched a A$653 million capital raising to fund the clinical advancement of four RNA-based drug candidates targeting genetic diseases with significant unmet needs. The raise extends the company’s cash runway to 2030, supporting key clinical milestones and a transition to commercialisation.

Adavale Resources has raised $5.15 million in a strongly supported placement to fund an expanded drilling program at its London Victoria Gold Mine and advance regional exploration efforts.

Accent Resources NL reports steady progress on its Magnetite Range Project pre-feasibility study, confirming high-grade magnetite concentrate, while maintaining stable gold resources at Norseman and holding nearly $10 million in cash.

Citigold Corporation continues to progress its high-grade Charters Towers Gold Project, maintaining stable mineral resources while advancing mine design and funding discussions. The company’s strategic focus on near-surface gold structures offers promising short-term mining opportunities.

Biotron Limited has successfully closed its fully subscribed rights issue, raising $1.52 million, and completed the acquisition of Sedarex Limited, positioning itself for growth in its diversified biotech portfolio.

Apollo Minerals has raised $6.5 million through a share placement to advance its Couflens High Grade Tungsten Gold Project in southern France, backed strongly by existing investors and company directors.

Magnetite Mines broadens its strategic partnerships and progresses key approvals for the Razorback Iron Ore Project, while uncovering new rare earth mineralisation and expanding its green iron consortium.

QMines Limited has made significant strides in its Queensland projects with high-grade drilling results at Mount Mackenzie and Develin Creek, backed by a $9 million capital raise to support exploration and development.

Alexium International Group has acquired Microtek Laboratories’ microencapsulation business, marking a strategic pivot to manufacturing-led growth and raising $4.6 million to fund expansion. Despite a slight sales dip, the company is poised for a stronger 2026 with new product lines and military trials underway.

Neurizon Therapeutics has cleared a major regulatory hurdle with the FDA lifting the clinical hold on its lead drug NUZ-001 and secured a comprehensive $33 million funding package to advance its pivotal ALS trial.